Parnax Lab

Parnax Lab FCF/Debt

The Free Cash Flow to Debt Ratio of Parnax Lab (506128.BO) as of Nov 22, 2026 is 19.74 %. In the previous year, Free Cash Flow to Debt Ratio was -20.61 % — a change of -195.79% (higher).

FCF/Debt

19.74 %

YoY

-195.79%

Last updated:

Free Cash Flow to Debt Ratio of Parnax Lab is 2025 19.74 % . Free Cash Flow to Debt Ratio of Parnax Lab was 2024 -20.61 % . It decreases by -195.79% higher compared to the previous year.

The Parnax Lab FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
20.89 INR
Jan 1, 2019
-6.21 INR
Jan 1, 2020
-8.66 INR
Jan 1, 2021
-0.39 INR
Jan 1, 2022
-13.44 INR
Jan 1, 2023
17.60 INR
Jan 1, 2024
-20.61 INR
Jan 1, 2025
19.74 INR
The Parnax Lab FCF/Debt history
YEARFCF/DebtYoY
19.74 %-195.79%
-20.61 %-217.10%
17.60 %-230.96%
-13.44 %+3,323.55%
-0.39 %-95.47%
-8.66 %+39.41%
-6.21 %-129.73%
20.89 %+1,729.57%
1.14 %-127.67%
-4.13 %-31.99%
-6.07 %-43.82%
-10.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Free Cash Flow to Debt Ratio of Parnax Lab is 19.74 % in 2025.

Free Cash Flow to Debt Ratio of Parnax Lab changed from -20.61 % to 19.74 %, representing a -195.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Parnax Lab

All Key Metrics — Parnax Lab